Top 50 Health Care VC (Venture Capital) Funds in Finland in January 2026

Butterfly Ventures is a seed-stage focused VC in the Nordics, investing in deep tech, hardware, and hardware interfacing software. The company prefers to get involved with companies early on; 80% of Butterfly Ventures portfolio companies don't have any revenue at the time of their entry. Butterfly Ventures was founded in 2012 and ever sincethen it has been one of the most active early stage VCs in the region. The company has offices in Oulu, Helsinki and Stockholm.

Lifeline Ventures Oy is a venture capital firm specializing in startups, growth capital, and early stage investments. The firm seeks to invest in healthcare, games, web based and general high technology sectors. It seeks to invest in Finland with a few investments made outside Finland as well. The firm targets investing between €0.5 million ($0.66million) and €1 million ($1.32 million). It seeks make inception to Series A investments. Lifeline Ventures Oy was founded in November 2009 and is based in Helsinki, Finland.

Business Finland finances business R&D projects and public research projects at universities, research institutes and universities of applied sciences. Read more about R&D and business funding.

Finnvera makes direct investments in early-stage enterprises through Seed Fund Vera Ltd. Finnvera's goal is to cover shortcomings existing on the market between product development funding and private equity investments. Finnvera does not compete with private financiers; instead, it strives to supplement the financial market.Finnvera'sinvestments enable, start and accelerate growth and internationalisation among investment targets. Enterprises are developed to make them attractive targets for further financing by other investors and industrial actors. Investments are made in technology enterprises at an early stage and in technology-intensive or innovative service enterprises that have potential for developing into international growth enterprises.Finnvera is also known as a specialised financing company owned by the State of Finland. It provides its clients with loans, guarantees, venture capital investments and export credit guarantees.

Finnish Industry Investment Ltd is a government-owned investment company. It invests the proceeds accrued from the privatisation of state-owned companies in stimulating the growth and internationalisation of Finnish businesses.Finnish Industry Investment invests in venture capital funds and directly in growth companies, together with privateco-investors. The targets are in all sectors. Capital investments are needed for financing the growth of investee companies, and for spin-offs, major industrial investments, and sector and corporate restructurings.The investments of Finnish Industry Investment amount to over MEUR 570

Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.

Founded in 2016, Icebreaker has invested in over 50 fast-growing tech startups built by domain expert founders from companies like Rovio, Nordea, Pipedrive, Eniram, IBM and BCG. In addition to the fund, Icebreaker also runs a community of more than 1000 founders and pre-founders with 5+ years of relevant industry experience and the will to start,build or join strong tech companies.With the initial ticket sizes of €150k - 800K Icebreaker provides enough funding for companies to get to a position of strength and avoid post-accelerator limbo without having to resort to disreputable sources of capital and unfriendly deal terms.

Innovestor is an active Finnish investment manager, focusing on venture capital, real estate, and energy storage. We also offer corporate venturing services.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

The Citizenship Fund started out when the founders of the company discovered in their previous positions that a promising Finnish growth company will spend a great deal of time and energy in arranging financing. A good business idea and a team with excellent team could take months in financial negotiations and the outcome could be a return to thestart-up. At the same time, investors often wanted new types of higher potential investments alongside traditional alternatives.These two challenges were possible by removing the promising growth companies as investors, even for non-traditional venture capital investors. Citizenship wanted to create a service in which the company would be able to capitalize on business quickly and flexibly, but the decision-making business would be left to the company itself. From today's point of view, Springvest's goal is that an increasing number of Finnish investors can get involved in the story of Finnish growth companies and potential success.

The Redstone team is an international and diverse group of serial entrepreneurs, investors, investment professionals, tech analysts and data scientists.

Reaktor Ventures has moved to the next phase by focusing its efforts to actively supporting current portfolio companies. This means that the fund has ended its investment period and is not investing into new companies. Between 2013 and 2018 we have invested into 42 different companies and one early stage fund. We will naturally keep makingfollow-up investments to current portfolio companies.

WE HELP YOU TO GROW FASTER!

Nidoco AB is a Swedish investment company whose strategy is to create long-term value through active ownership of public and private companies.

We partner with founders to transform unseen scientific discoveries into future breakthroughs, jointly moving businesses, people, and the world forward.

VTT is a powerhouse of technology development and scientific research. Many of the most significant Finnish technology start-ups were brought to life at VTT. Do you want to invest in ongoing ventures?

Maki.vc is an early-stage venture capital firm partnering with deep tech & brand-driven startups obsessed with challenging category norms.

Oy Hammaren & Co Ab provides financial services and insurance activities.

First Fellow Partners is a private investment firm built on a founder-first philosophy. We invest only our own capital, backing bold, mission-driven technology entrepreneurs from idea to lasting impact.

Sitra is the venture capital investment arm of Sitra specializing in investments in seed, start-ups, early stage opportunities, and other funds. The firm invests through its three programmes namely, Health Care Programme, the Food and Nutrition Programme, and the Environmental Programme. Within the Health Care Programme, investments are focused oncompanies engaged in paper-free health care, seamless services, decentralised specialised health care, and support services. Within the Food and Nutrition Programme, investments are made in enterprises engaged in the food and nutrition sector, including value-adding upgrading of raw materials and new applications and service concepts in food and nutrition technology.

Cor Group management consulting firm serving Psychological, Educational, and Behavioral Services.

Athensmed Oy

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Nostetta Ventures is a venture capital company investing in growth companies mainly in the North Savo region.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Pontos is a family owned Finnish private equity and real estate investment company operating in Finland, the Baltic States, and Portugal.

Metsola Ventures

Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds

Some call you founders. We call you Superheroes. Seed stage VC investing in insight-driven startups in Finland and the Baltics.

Alliance Venture is a Nordic venture capital firm investing in exceptional early-stage tech companies and purpose-driven founders with global ambitions. Offices in Oslo, Stockholm, Copenhagen and Helsinki.

Samsung Venture Investment is plays the role of driving the discovery and development of new businesses and technologies.

Gorilla Capital helps ambitious startups grow with smart funding and support. Discover how our team invests in early-stage companies.

Conor Venture Partners is a new breed technology venture capital fund and management company. Conor invests in early-stage companies originating from Nordic and Baltic countries. Investment areas include information and communications technology, embedded software, semiconductor technology, electronics, new materials and optics.

The University of Helsinki has the widest range of disciplines in Finland. It was established in Turku in 1640, but was transferred to Helsinki in 1828. The number of faculties is eleven. There are 35,000 degree students and 7,900 staff. The number of degrees taken each year is an average 5,000, of which about 470 are doctorates. The Universityconcentrates on high-level scientific research and researcher education. Scientific research is also the basis of the teaching provided by the University. The University operations support the development of society, as well as business and industry. University representatives offer their competencies for the benefit of society through a number of positions of trust and expertise. The results produced by the research and teaching carried out at the University have been widely acclaimed. The University participates in more than half of the national Centres of Excellence in Research, elected by international scientific panels. The University of Helsinki has been invited to be a member of the League of European Research Universities, a co-operation body for the leading European research universities. According to international expert panels, also the teaching provided by the University of Helsinki is of a high European level. The University has strong international connections. It has some 80 co-operation agreements with universities on different continents. The University researchers are in great demand as experts in international scientific communities, meetings and publications. The University is bilingual, but in addition to Finnish and Swedish teaching is also provided in English. Besides Helsinki, the University has operations at 20 localities throughout Finland.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

We fund futurebreakthroughs

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

Korpun Siemen is backed by 33 investors who have combined their initial investment activities and have extensive experience in start-up, growth and family businesses in various industries. The company includes active angel investors, entrepreneurs in growth companies and investors who have already exited their companies.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.

cross-border, healthcare, life science, investment, VC, China, US

Almaral provides risk management advice long-term strategy development budgeting operational function setup legal support early-stage sales and marketing function setup, and commercialization.

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

Illusian is the Founder Office of people who have founded and scaled companies like Supercell, Zalando, Wolt, Aiven, Pigment, and Smartly. While the group is still busy running their businesses, they've aligned their networks, capital, and expertise to simultaneously support the next generation of builders.

Heraeus, the technology group headquartered in Hanau, Germany, is a leading international family-owned portfolio company.

Co-operative Tradeka is a consumer co-operative involved in the restaurant business and involved in investment activities.Co-operative Tradeka is a consumer co-operative founded in the year 1917. Nowadays, the Co-operative serves approximately 225 000 members. The Co-operative Tradeka is a management co-operative, which is the owner of TradekaGroup Ltd (98%) and Tradeka-services Ltd (100%) (responsible for the membership benefits of the Co-operative). The CEO of the Co-operative Tradeka is Perttu Puro, Master of Laws.Tradeka Ltd is the sole owner of Restel Oy (involved in the restaurant business) and Tradeka-invest Ltd (involved in investment activities) The CEO Tradeka Ltd is Perttu Puro, Master of Laws.